SEC Form 4 · accession 0001562180-18-004189
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay Strum
Officer — Chief Scientific Officer
Period of report
Oct 4, 2018
Accepted (ET)
Oct 5, 2018 · 6:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 4, 2018 | M | 850 | $0.30 | A | 49,419 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $0.30 | Oct 4, 2018 | M | 850 | D | — | Nov 9, 2022 | Common Stock | 850 | 15,816 | D |
Explanation of responses
- F1All shares underlying this option have vested.